aHUS

1.     Optimal Duration of Complement Inhibitor Therapy: No consensus on how long to continue complement inhibitors (Anti-C5 therapy).

2.      Long-Term Safety and Outcomes of Complement Inhibitors: Limited long-term safety data (especially in children) on prolonged complement blockade.

3.     Relapse Prediction and Early Detection: limitation of the presence of reliable biomarkers for relapse post-treatment.

4.     The validity of liver transplantation in correcting complement dysregulation in aHUS remains unclear and requires further investigation.